Search PubMed⌕ Search

Biomedical subjects

S R Hollingsworth

Publications and source records attributed to S R Hollingsworth.

2 recordsLinked to original sources

Canine protothecosis.

Canine protothecosis remains a difficult condition to manage. The paucity of clinical cases hinders the development of successful treatment strategies. The clinical signs associated with the disease are nonspecific, and the course is so insidious that, by the time a definitive diagnosis is reached, the organism has often disseminated throughout the body. At this point, the condition is beyond treatment, and death occurs owing to failure of any number of organ systems, including the gastrointestinal, cardiovascular, renal, and central nervous systems. It is of some encouragement that the few patients that have undergone aggressive early treatment have survived longer than patients presenting late in the disease course. Nevertheless, the outlook for any dog with protothecosis is grave, and it remains to be determined whether early diagnosis can truly provide a better long-term prognosis. By including protothecosis as a consideration for dogs initially brought in with a history of chronic diarrhea or acute blindness and with a subsequent finding of exudative retinal separation, early diagnosis is possible. This recognition potentially affords the opportunity for an immune status work-up and intervention with increasingly better treatment options.

Animals↗

Effect of topically administered atropine on tear production in dogs.

Baseline tear production values were established for both eyes of 19 dogs, using the Schirmer tear test. Atropine sulfate, 1% solution, was administered topically in the left eye of each dog once daily for 14 days. Tear production was then determined for both eyes at 15, 30, 60, 120, 180, 240, and 300 minutes, and 3, 6, 9, 12, and 15 days. A final Schirmer tear test reading was obtained for each eye 5 weeks after the last atropine treatment to check for the possibility of prolonged effect. Both eyes had statistically significant (P less than 0.05) decrease in tear production that was most marked at 120 minutes after atropine instillation, then returned to baseline values by 300 minutes after instillation. Although atropine was placed in the left eye only, statistically significant difference was not apparent in Schirmer tear test values between the left and right eyes. Tear production continued to decrease in both eyes over time, becoming statistically significant (P less than 0.05) on day 9. However, on days 12 and 15, tear production in the untreated eye plateaued, but that in the treated eye continued to decrease. Five weeks after the last treatment with atropine, both eyes still had a statistically significant (P less than 0.05) decrease in tear production, although Schirmer tear test values had increased from day-15 values and appeared to be returning to baseline. Association was not evident between age or body weight and magnitude of response to topically applied atropine.

Administration, Topical↗